At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 32 enrolled

Drug / intervention

CP-675,206biological

Likely dose

CP-675,206 15mg/kgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00471887

NCT00471887Phase 2Completed

Compare CT.gov

A Phase II, Open-Label, Single Arm Clinical Trial to Study the Mechanism of Action of CP-675,206 in Patients With In-Transit and Metastatic Melanoma Amenable to Repeated Outpatient Tumor Biopsies

Jonsson Comprehensive Cancer Center·interventional·Posted May 10, 2007·Updated Oct 26, 2020

In Brief

A Phase 2 clinical trial evaluating CP-675,206 for Melanoma (Skin). Completed, enrolled 32 participants across 1 site.

Detailed Summary

RATIONALE: Monoclonal antibodies, such as ticilimumab (CP-675,206), can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well ticilimumab (CP-675,206) works in treating patients with stage IIIC or stage IV melanoma.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMelanoma (Skin)

CountriesUnited States

CollaboratorsPfizer

Timeline

Phase 2CompletedFinished

200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Enrollment StartJan 2007

First PostedMay 2007

Primary CompletionJul 2011

Study CompletionMar 2015

TodayJul 2026

First PostedMay 10, 2007

Enrollment StartJan 1, 2007

Primary CompletionJul 1, 2011

Study CompletionMar 1, 2015

TodayJul 2, 2026

Enrollment to primary: 4.5 yearsPosted 19.1 years ago

Interventions

CP-675,206biological

Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.